08HH Stock Overview
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥1.69 |
| 52 Week High | CN¥2.32 |
| 52 Week Low | CN¥1.29 |
| Beta | 0.72 |
| 1 Month Change | -2.60% |
| 3 Month Change | 7.53% |
| 1 Year Change | -12.03% |
| 3 Year Change | -53.65% |
| 5 Year Change | n/a |
| Change since IPO | -59.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| 08HH | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.2% | -0.3% | -0.2% |
| 1Y | -12.0% | -17.0% | 7.0% |
Return vs Industry: 08HH exceeded the German Pharmaceuticals industry which returned -17% over the past year.
Return vs Market: 08HH underperformed the German Market which returned 7% over the past year.
Price Volatility
| 08HH volatility | |
|---|---|
| 08HH Average Weekly Movement | 11.2% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 08HH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 08HH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 39,309 | Deyong Wen | www.fosunpharma.com |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company’s product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the treatment of carbapenem resistant enterobacteriaceae (CRE) infection; XH-S003 for the treatment of IgA nephropathy and other glomerular diseases; HLX43, an antibody-drug for the treatment of metastatic solid tumors; XS-03 for the treatment of RAS-mutated advanced solid tumor; OP0595, a nacubactam for the treatment of aerobic gram-negative bacteria; XH-S002 for the treatment of ischemic stroke and transient ischemic attack which are in Phase I; HLX26, anti-LAG-3 humanized monoclonal antibody injection for the treatment of metastatic colorectal cancer; FCN-338 for the treatment of myeloid malignancies; FCN-159 for the treatment of langerhans cell histiocytosis; HLX208, a BRAF V600E inhibitor for the treatment of non-small cell lung cancer which are in phase II; FS-1502, a HER2 humanized monoclonal antibody-monomethyl auristatin F injection for the treatment of HER2-positive locally advanced or metastatic breast cancer; FCN-159 for the treatment of neurofibromatosis; ET-26, a methoxyetomidate hydrochloride for the treatment of general anesthesia which are in phase III.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fundamentals Summary
| 08HH fundamental statistics | |
|---|---|
| Market cap | €7.96b |
| Earnings (TTM) | €278.22m |
| Revenue (TTM) | €5.48b |
32.1x
P/E Ratio1.6x
P/S RatioIs 08HH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 08HH income statement (TTM) | |
|---|---|
| Revenue | CN¥41.61b |
| Cost of Revenue | CN¥21.83b |
| Gross Profit | CN¥19.78b |
| Other Expenses | CN¥17.67b |
| Earnings | CN¥2.11b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 26, 2025
| Earnings per share (EPS) | 0.80 |
| Gross Margin | 47.55% |
| Net Profit Margin | 5.08% |
| Debt/Equity Ratio | 55.0% |
How did 08HH perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield34%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 18:43 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is covered by 31 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Zhang | BNP Paribas Securities (Asia) |
| Wai Chak Yuen | BOCI Research Ltd. |
| Yang Huang | BofA Global Research |